Core Points - BioStem Technologies, Inc. has partnered with the Florida Panthers to sponsor the "Heroes Among Us" program, which honors military veterans during NHL home games [1][2] - The program has recognized over 500 military members since its inception in 2013, including veterans from various wars [2] - BioStem is also continuing its support for the "Seats for Service" initiative, providing game-day experiences for veterans and their families [4] Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [1][8] - The company utilizes its proprietary BioREtain® processing method to maintain growth factors and preserve tissue structure in its products [8] - BioStem's quality management system is accredited by the American Association of Tissue Banks, adhering to current Good Tissue Practices and Good Manufacturing Processes [8] Community Engagement - The "Heroes Among Us" program features a military hero at each home game, with a national anthem dedication and a video highlighting their story [2][3] - The Florida Panthers Foundation emphasizes veterans' affairs as one of its core pillars, supporting organizations that provide resources to military members [5] - The community can nominate veterans for the "Heroes Among Us" program through the Florida Panthers' website [3]

Summary of BioStem Technologies FY Conference Call Company Overview - **Company**: BioStem Technologies (OTCPK:BSEM) - **Industry**: Advanced Wound Care - **Market Size**: The advanced wound care market is valued at **$11.3 billion**, with a significant portion in the wound biologic segment at **$8.5 billion** [2][6] Core Business and Technology - **Proprietary Technology**: BioStem has developed **BioREtain®**, a technology that enhances wound healing by retaining key growth factors [3][7] - **Patent Portfolio**: The company holds **55 issued patents** and **53 pending patents** related to its technologies [3] - **Product Offerings**: Currently, BioStem has **five products** targeting diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs) [3] Financial Performance - **Revenue**: In 2024, BioStem reported over **$300 million** in top-line revenue and over **$39 million** in adjusted EBITDA [4] - **Cash Position**: As of June 30, 2025, the company had over **$30 million** in cash on hand [4][21] - **Growth Trajectory**: Revenue growth from under **$16 million** in 2023 to over **$300 million** in 2024, indicating a significant upward trend [19] Market Dynamics - **Patient Demographics**: There are over **7 million Medicare patients** with chronic non-healing wounds, with projections indicating a **20% increase** by 2030 [4][5] - **Wound Types**: Pressure ulcers account for **41%**, diabetic foot ulcers for **30%**, and venous leg ulcers for **11%** of the chronic wound market [4] Clinical Trials and Research - **Ongoing Studies**: BioStem is conducting clinical trials for DFUs and VLUs, with results expected by the end of 2025 [8][9] - **Real-World Data**: The BioREtain® technology has shown a **25% reduction** in the number of applications needed compared to competitor products [6] Reimbursement Landscape - **Current Reimbursement**: Products are currently reimbursed at approximately **$1,780** in hospital outpatient settings and **$860** in ambulatory surgery centers [13] - **Future Changes**: Anticipated changes in 2026 may lead to a flat-rate reimbursement model across all service sites, which could stabilize pricing and improve margins [13][14] Strategic Initiatives - **Expansion Plans**: BioStem aims to expand its commercial team and increase penetration in various healthcare settings, including the VA segment [16][22] - **Product Development**: The company is looking to innovate its BioREtain® process and explore strategic acquisitions to enhance its product portfolio [17] Management and Team - **Leadership Changes**: Recently appointed CFO Brandon Poe and marketing head Barry Hassett are expected to drive future growth [21][22] Conclusion - **Market Outlook**: The chronic wound care market is expected to grow, and BioStem is well-positioned to capitalize on this growth through innovative products and strategic partnerships [22][23]

Core Insights - BioStem Technologies, Inc. has appointed Brandon Poe as Chief Financial Officer, marking a significant leadership change during a period of growth and innovation for the company [1][2] - The company is recognized for its innovative wound care technologies and aims to leverage its BioREtain® platform to accelerate growth and expand market presence [3] Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [1] - The company utilizes its proprietary BioREtain® processing method, which is designed to maintain growth factors and preserve tissue structure [3] - BioStem's quality management system has been accredited by the American Association of Tissue Banks and adheres to current Good Tissue Practices and Good Manufacturing Processes [3] Leadership Background - Brandon Poe brings over 25 years of experience in finance within the healthcare and life sciences sectors, having previously served as CFO at Midi Health, Inc. and Jumpcode Genomics, Inc. [2] - His experience at Illumina, Inc. included multiple senior finance roles, enhancing his capability to contribute to BioStem's strategic goals [2] Strategic Goals - The company aims to expand into new markets and advance its plans for a Nasdaq uplisting, indicating a focus on long-term growth ambitions [2] - Brandon Poe expressed enthusiasm about driving value for shareholders and executing the company's strategy during this pivotal stage [3]

Core Points - BioStem Technologies Inc. will release its second quarter 2025 financial results on August 14, 2025, and will host a conference call and webcast at 4:30 PM ET [3][4] - The conference call will include a review of the financial results and updates on the Company's Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato [4] - BioStem Technologies focuses on the development, manufacture, and commercialization of placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method [6][7] Company Overview - BioStem Technologies is recognized as a leading innovator in the MedTech sector, specializing in allografts for advanced wound care [6] - The Company’s quality management systems are accredited by the American Association of Tissue Banks (AATB) and comply with Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [7] - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE®, and American Amnion™, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida [7]